{
  "@context": {
    "m0": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M0_ComplexChemicalSynapse.jsonld#",
    "m2": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M2_Metaconcepts.jsonld#",
    "m3eagle": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M3_EagleEye.jsonld#",
    "m3sphinx": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M3_SphinxEye.jsonld#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "owl": "http://www.w3.org/2002/07/owl#",
    "xsd": "http://www.w3.org/2001/XMLSchema#",
    "dcterms": "http://purl.org/dc/terms/"
  },
  "@graph": [
    {
      "@id": "m0:ComplexChemicalSynapse",
      "@type": "owl:Ontology",
      "dcterms:title": "Complex Chemical Synapse - TSCG M0 Poclet",
      "dcterms:description": "A 5-pole interdependent system modeling synaptic transmission through neurotransmitter synthesis, vesicular storage, exocytotic release, postsynaptic reception, and signal termination. Demonstrates high-dimensional biological coordination and serves as pharmacological intervention framework.",
      "dcterms:creator": "Echopraxium with collaboration of Claude AI",
      "dcterms:created": "2026-01-21",
      "dcterms:modified": "2026-01-21",
      "owl:versionInfo": "1.0.0",
      "owl:imports": [
        "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M2_Metaconcepts.jsonld",
        "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M3_EagleEye.jsonld",
        "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M3_SphinxEye.jsonld"
      ],
      "rdfs:seeAlso": "https://raw.githubusercontent.com/Echopraxium/tscg/main/docs/M0_ComplexChemicalSynapse_Analysis.md",
      "dcterms:subject": ["Neurobiology", "Cellular Communication", "Synaptic Transmission", "Pharmacology"],
      "m0:domain": "Neuroscience",
      "m0:pocletType": "Territory-dominant biological system with pedagogical Map",
      "m0:poleCount": 5,
      "m0:phenomenon": "Precise, rapid, and temporally controlled synaptic transmission enabling neural information processing through chemical signaling between neurons",
      
      "m0:territoryDescription": {
        "physicalReality": "Synapse: specialized junction between neurons where electrical signals are converted to chemical signals (neurotransmitter release) and back to electrical signals (postsynaptic potential). Structure includes presynaptic terminal (vesicles, active zone), synaptic cleft (~20-40 nm), and postsynaptic density (receptors, signaling machinery).",
        "observability": "Accessible with modern neuroscience tools: electron microscopy (ultrastructure), patch-clamp electrophysiology (currents), fluorescence microscopy (calcium imaging, vesicle dynamics), optogenetics (controlled activation)",
        "timescale": "Milliseconds (0.5-5 ms transmission latency)",
        "spatialScale": "Nanometers to micrometers (cleft ~20-40 nm, active zone ~1 μm²)",
        "evolutionaryContext": "Emerged ~600 million years ago during Cambrian explosion. Conserved across species from C. elegans to humans. Enables rapid, precise, and modifiable neural communication."
      },

      "m0:mapDescription": {
        "conceptualModel": "5-Pole Sequential Interdependence Model",
        "purpose": "Provides conceptual framework for understanding synaptic function, guiding pharmacological interventions, and teaching neuroscience. Decomposes continuous biochemical cascade into discrete functional stages.",
        "pedagogy": "Standard model in neuroscience textbooks (Kandel et al. Principles of Neural Science). Each pole represents druggable target.",
        "limitations": "Simplifies continuous process into discrete poles. Underrepresents glial cell contribution (astrocytes, microglia). Ignores nanoscale organization (liquid-liquid phase separation, nanodomains). Temporal averaging (model operates at ms scale, some processes are sub-ms).",
        "historicalDevelopment": "Loewi (1921) chemical transmission → Katz (1951) quantal release → Südhof (1990s) SNARE mechanism → Current 5-pole integration model"
      },

      "m0:bicephalousAnalysis": {
        "description": "Dual perspective analysis - Eagle Eye (ASFID Territory measurement) + Sphinx Eye (ORIVE Map interpretation)",
        
        "eagleEye": {
          "@id": "m3eagle:EagleEye",
          "rdfs:seeAlso": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M3_EagleEye.jsonld",
          "role": "Quantitative measurement of synaptic Territory",
          
          "territoryASFID": {
            "accessibility": {
              "score": 0.65,
              "rationale": "Moderate-High. Requires specialized equipment (electron microscopy, patch-clamp, fluorescence imaging, optogenetics). Nanoscale structures (vesicles ~40 nm) and millisecond events. Invasive techniques needed. Highly reproducible in controlled conditions."
            },
            "stability": {
              "score": 0.75,
              "rationale": "High. Stereotyped process with high-fidelity transmission. Conserved across species >500 million years. Stable parameters (quantal size ~7000 molecules/vesicle). Variability from plasticity and stochastic release (P_release ~0.1-0.9) but predictable."
            },
            "flow": {
              "score": 0.90,
              "rationale": "Very High. Rich material flows (precursors→NT→vesicles→release→receptors→degradation), energy flows (ATP for vesicle loading and ion gradients), information flows (action potential→Ca²⁺→NT→EPSP/IPSP). Measurable flux rates. Critical temporal dynamics (~0.5-5 ms)."
            },
            "interoperability": {
              "score": 0.70,
              "rationale": "High. Extreme interdependence between poles - failure of any pole destroys transmission. Molecular interfaces (NT-receptor binding, K_d ~nM-μM), spatial interfaces (cleft geometry), temporal interfaces (synchronization ~0.2-0.5 ms jitter). Feedback via autoreceptors. Network integration (100s-1000s synapses per neuron)."
            },
            "determination": {
              "score": 0.80,
              "rationale": "High. Highly deterministic at macroscopic level. Action potential→Ca²⁺ entry is deterministic. Ca²⁺→fusion is stochastic but predictable (Poisson/binomial). Quantal analysis and cable theory yield accurate predictions. Pharmacology highly predictable (dose-response curves). Ca²⁺ absolutely required for release. SNARE+vesicle+Ca²⁺ sufficient for fusion (in vitro reconstitution)."
            },
            "vectorNotation": "|Ω_synapse⟩ = 0.65|A⟩ + 0.75|S⟩ + 0.90|F⟩ + 0.70|I⟩ + 0.80|D⟩",
            "ASFIDmean": 0.76,
            "quality": "Good Territory accessibility"
          },

          "measurements": {
            "vesicleCount": "Readily releasable pool: ~10-20 vesicles per active zone",
            "quantalSize": "~7000 neurotransmitter molecules per vesicle (neuromuscular junction)",
            "cleftWidth": "20-40 nanometers",
            "activeZoneArea": "~1 μm² (diameter ~300-500 nm)",
            "transmissionLatency": "0.5-5 milliseconds",
            "diffusionTime": "~100 microseconds (cleft crossing)",
            "releaseProbability": "0.1-0.9 depending on synapse type and activity state",
            "Ca2+cooperativity": "4th order (fusion probability ∝ [Ca²⁺]⁴)",
            "receptorAffinity": "K_d ~nanomolar to micromolar range",
            "reuptakeRate": "Variable by transporter (SERT, DAT, NET have distinct kinetics)",
            "enzymeKinetics": "Acetylcholinesterase: K_m ~100 μM, k_cat ~10⁴ s⁻¹"
          },

          "formulas": {
            "quantalContent": "m = n × P_release (n=vesicles in RRP, P_release=fusion probability)",
            "EPSCamplitude": "EPSC = m × q (m=quantal content, q=quantal size)",
            "calciumCooperativity": "P_fusion ∝ [Ca²⁺]⁴ (Hill coefficient ~4)",
            "diffusion": "t_diffusion ≈ x²/(2D) where x=cleft width, D=diffusion coefficient",
            "receptorOccupancy": "θ = [NT]/([NT] + K_d) (Michaelis-Menten)",
            "synapticIntegration": "V_m = Σ(EPSP_i - IPSP_j) (spatial and temporal summation)"
          },

          "calculations": {
            "energyCost": "ATP consumed in: vesicle loading (~1 ATP/NT via H⁺-ATPase), Na⁺/K⁺ pump (~1 ATP per 3 Na⁺ out, 2 K⁺ in), Ca²⁺ extrusion (~1 ATP per 1-2 Ca²⁺)",
            "informationRate": "~1-100 spikes/second typical (maximum ~1000 Hz limited by refractory period)",
            "molecularFlux": "NT molecules released per second: ~10⁴-10⁶ depending on firing rate and quantal size",
            "signalToNoise": "High at neuromuscular junction (safety factor ~5-10), lower at central synapses (safety factor ~1-2)"
          }
        },

        "sphinxEye": {
          "@id": "m3sphinx:SphinxEye",
          "rdfs:seeAlso": "https://raw.githubusercontent.com/Echopraxium/tscg/main/ontology/M3_SphinxEye.jsonld",
          "role": "Qualitative interpretation of synaptic Map",
          
          "mapORIVE": {
            "operationalizability": {
              "score": 0.85,
              "rationale": "High. Model makes concrete, testable predictions. Blocking any pole (e.g., botulinum toxin→SNARE cleavage→zero transmission) yields expected outcome. Each pole quantifiable (enzyme assays, vesicle counting, patch-clamp, HPLC). Highly actionable in pharmacology - each pole is druggable target. Validated over century of experiments."
            },
            "refutability": {
              "score": 0.90,
              "rationale": "Very High. Highly falsifiable. Example: 'Block Ca²⁺ channels→block release' tested with Cd²⁺/ω-conotoxin and confirmed. Model predicts specific molecular players (not vague). Historical tests survived rigorous scrutiny (Loewi 1921, Katz 1951, Südhof 1990s). Rare counterexamples (non-quantal leak, transporter reversal) are minor. Boundary conditions well-defined (chemical synapses, not electrical gap junctions)."
            },
            "internalCoherence": {
              "score": 0.80,
              "rationale": "High. No internal contradictions. Poles are logically sequential and causally linked. Energy budgets balance (ATP consumption accounted for). Unified framework consistent with thermodynamics, kinetics, molecular biology. Feedback loops (autoreceptors) internally consistent. Reasonably parsimonious (5 poles necessary, not over-complicated)."
            },
            "validationStatus": {
              "score": 0.95,
              "rationale": "Very High. Overwhelming empirical support: 100+ years data across species (worms to humans). Molecular components cloned and characterized. Near-universal scientific consensus (standard textbook model). Nobel Prizes awarded (Katz 1970, Carlsson 2000, Südhof/Rothman 2013). Cross-validation from electrophysiology, biochemistry, molecular biology, imaging. In vitro reconstitution validates mechanisms. Minimal anomalies."
            },
            "explanatoryPower": {
              "score": 0.85,
              "rationale": "High. Explains diverse phenomena: normal transmission, synaptic plasticity (LTP/LTD), drug action, diseases. Mechanistic depth (molecular details). Multi-scale (molecules→synapses→circuits→behavior). Unifies neuroscience, pharmacology, medicine. Generates new insights (predicts drug targets, explains pathology). Limitations acknowledged (simplifies glial contribution, nanodomains)."
            },
            "vectorNotation": "|M_synapse⟩ = 0.85|O⟩ + 0.90|R⟩ + 0.80|I⟩ + 0.95|V⟩ + 0.85|E⟩",
            "ORIVEmean": 0.87,
            "quality": "Excellent Map"
          },

          "interpretations": {
            "purpose": "Conceptual framework for understanding neural communication, guiding drug development, and teaching neuroscience. Decomposes complex cascade into manageable functional units.",
            "strength": "Each pole is independently modulable (druggable). Model balances detail (5 poles) with simplicity (not 50 poles). Actionable for pharmacology (100+ validated drugs).",
            "limitation": "Simplifies continuous biochemical process. Underrepresents glial cells (astrocytes, microglia), nanodomains, non-canonical pathways (non-vesicular release, volume transmission). Temporal resolution (ms) but sub-ms events exist.",
            "emergence": "Information processing emerges from molecular interactions. Consciousness (debated) may emerge from synaptic network dynamics. Learning emerges from synaptic plasticity.",
            "evolutionaryInsight": "5-pole structure reflects evolutionary optimization for controllability and modularity. Each pole = intervention point for natural selection or pharmacology.",
            "tradeOffs": "Speed vs. Reliability (fast synapses like auditory vs. reliable like neuromuscular). Plasticity vs. Stability (modifiable synapses vs. hardwired circuits). Precision vs. Robustness (temporal precision vs. noise tolerance). Energy vs. Performance (high-fidelity costs ATP)."
          },

          "historicalContext": {
            "origin": "Loewi (1921): Chemical transmission hypothesis (Vagusstoff experiment). Dale (1935): Acetylcholine identification. Katz (1951): Quantal release theory.",
            "evolution": "1950s: Electron microscopy reveals vesicles. 1970s-80s: Receptor cloning. 1990s: SNARE mechanism (Südhof, Rothman). 2000s-present: Super-resolution imaging, optogenetics.",
            "adoption": "Universal model in neuroscience. Pharmaceutical industry uses pole-targeting framework."
          },

          "significance": {
            "scientific": "Fundamental to neuroscience. Validates molecular neurobiology paradigm.",
            "medical": "Explains neurological diseases (Lambert-Eaton, myasthenia gravis), psychiatric disorders (depression, schizophrenia). Guides treatment.",
            "technological": "Enables optogenetics, brain-machine interfaces, neural prosthetics.",
            "philosophical": "Demonstrates reductionism's power (behavior explained by molecules). Also limits (consciousness not yet reduced to synapses)."
          }
        },

        "epistemicGap": {
          "formula": "ΔΘ(M) = ‖P(Reality) - Model‖",
          "value": 0.25,
          "interpretation": "Small gap. Model closely tracks reality. ASFID=0.76 (Good Territory access) and ORIVE=0.87 (Excellent Map) yield ΔΘ≈0.25.",
          "gapSources": [
            "Temporal resolution: Model averages over sub-millisecond events (e.g., single-channel kinetics, Ca²⁺ nanodomains)",
            "Spatial simplification: Ignores nanoscale organization (liquid-liquid phase separation, super-resolution structure)",
            "Stochasticity: Individual vesicle behavior vs. ensemble statistics",
            "Glial cells: Astrocytes (glutamate uptake, K⁺ buffering), microglia (synaptic pruning) underrepresented",
            "Non-canonical pathways: Non-vesicular release, volume transmission, astrocytic gliotransmission"
          ],
          "acceptability": "Gap is acceptably small for pharmacology, clinical medicine, and neuroscience research. Model is reliable and predictive.",
          "futureReduction": "Could reduce gap by: (1) Adding Pole 6: Glial Modulation, (2) Multi-scale modeling (nano→meso→network), (3) Incorporating stochastic models explicitly"
        },

        "binocularSynthesis": {
          "depthPerception": "Eagle measures (ASFID=0.76) + Sphinx interprets (ORIVE=0.87) → Epistemic depth ΔΘ=0.25 reveals ~75% of complexity captured",
          "workflow": [
            "1. Sphinx asks: What is synaptic transmission? Why does it matter? (Purpose: neural communication, pharmacology)",
            "2. Eagle measures: Vesicle counts, quantal size, transmission latency, Ca²⁺ cooperativity, receptor affinity",
            "3. Sphinx interprets: Gap ΔΘ=0.25 means 'Excellent model with known limitations (glial cells, nanodomains)'",
            "4. Synthesis: Model is reliable for drug development, disease understanding, teaching - but not complete (future refinements needed)"
          ],
          "insight": "5-pole structure is not arbitrary - it reflects evolutionary optimization for controllability (each pole = intervention point) and modularity (independent tuning). Interdependence creates vulnerability (single-point failures cause disease) but also enables precise pharmacological targeting.",
          "outcome": "Quantified, contextualized understanding. Model is validated (ORIVE=0.87), actionable (pharmacology), and improvable (ΔΘ=0.25 suggests 25% missing complexity)."
        }
      }
    },

    {
      "@id": "m0:Pole1_Synthesis",
      "@type": ["owl:NamedIndividual", "m0:SynapticPole"],
      "rdfs:label": "Pole 1: Neurotransmitter Synthesis",
      "m0:poleNumber": 1,
      "m0:location": "Presynaptic neuron cytoplasm",
      "m0:function": "Enzymatic synthesis of neurotransmitter molecules from precursors",
      
      "m0:requirements": {
        "enzymes": [
          "Choline acetyltransferase (ACh synthesis)",
          "Tyrosine hydroxylase (catecholamine synthesis - rate-limiting)",
          "DOPA decarboxylase (dopamine synthesis)",
          "Dopamine β-hydroxylase (norepinephrine synthesis)",
          "Tryptophan hydroxylase (serotonin synthesis)",
          "Glutamic acid decarboxylase (GABA synthesis)"
        ],
        "precursors": [
          "Choline + Acetyl-CoA → Acetylcholine",
          "Tyrosine → L-DOPA → Dopamine → Norepinephrine → Epinephrine",
          "Tryptophan → 5-Hydroxytryptophan → Serotonin (5-HT)",
          "Glutamate → GABA"
        ],
        "energySource": "ATP for enzyme activity and precursor transport"
      },

      "m0:output": "Neurotransmitter molecules in cytoplasm",
      
      "m0:regulation": {
        "feedbackInhibition": "End-product inhibition (e.g., dopamine inhibits tyrosine hydroxylase)",
        "transcriptional": "Chronic activity regulates enzyme expression",
        "availability": "Precursor availability limits synthesis (e.g., dietary tryptophan for serotonin)"
      },

      "m0:pharmacologicalTargets": {
        "L-DOPA": "Dopamine precursor, bypasses tyrosine hydroxylase (Parkinson's disease)",
        "alphaMethyltyrosine": "Tyrosine hydroxylase inhibitor (pheochromocytoma)",
        "Carbidopa": "Peripheral DOPA decarboxylase inhibitor (prevents peripheral L-DOPA conversion, enhances CNS delivery)"
      },

      "m0:pathology": {
        "Parkinsons": "Substantia nigra dopamine neuron degeneration → insufficient dopamine synthesis",
        "PKU": "Phenylalanine hydroxylase deficiency → cannot synthesize tyrosine → catecholamine deficiency"
      },

      "m0:metaconceptsInvolved": [
        "m2:Process",
        "m2:Transformation",
        "m2:Constraint",
        "m2:Regulation",
        "m2:Component"
      ]
    },

    {
      "@id": "m0:Pole2_Storage",
      "@type": ["owl:NamedIndividual", "m0:SynapticPole"],
      "rdfs:label": "Pole 2: Vesicular Storage",
      "m0:poleNumber": 2,
      "m0:location": "Synaptic vesicles in presynaptic terminal",
      "m0:function": "Packaging and protection of neurotransmitter from cytoplasmic degradation",
      
      "m0:mechanism": {
        "vesicleSize": "~40 nm diameter small synaptic vesicles",
        "transporters": [
          "VMAT1/2 (Vesicular Monoamine Transporter - dopamine, norepinephrine, serotonin)",
          "VAChT (Vesicular Acetylcholine Transporter)",
          "VGLUT1/2/3 (Vesicular Glutamate Transporter)",
          "VIAAT/VGAT (Vesicular Inhibitory Amino Acid Transporter - GABA, glycine)"
        ],
        "energetics": "H⁺-ATPase creates proton gradient (acidic vesicle interior, pH ~5.5). NT/H⁺ antiporter uses gradient to concentrate NT (1000-10000 fold).",
        "protection": "Vesicular membrane prevents enzymatic degradation by cytoplasmic enzymes"
      },

      "m0:output": "Neurotransmitter-loaded vesicles ready for exocytosis",
      
      "m0:pools": {
        "readilyReleasablePool": "~10-20 vesicles docked at active zone, immediately available",
        "recyclingPool": "~50-100 vesicles, replenish RRP within seconds",
        "reservePool": "~1000+ vesicles, mobilized during sustained activity"
      },

      "m0:pharmacologicalTargets": {
        "Reserpine": "VMAT inhibitor, depletes monoamine vesicles (historical antipsychotic/antihypertensive, now rarely used due to depression side effect)",
        "Tetrabenazine": "VMAT2 inhibitor (Huntington's chorea - reduces dopamine)",
        "Vesamicol": "VAChT inhibitor (research tool, not clinical)"
      },

      "m0:pathology": {
        "LambertEatonSyndrome": "Autoantibodies against presynaptic Ca²⁺ channels reduce vesicle docking/release",
        "VMAT2mutations": "Rare genetic disorder causing infantile parkinsonism-dystonia"
      },

      "m0:metaconceptsInvolved": [
        "m2:Component",
        "m2:Space",
        "m2:Constraint",
        "m2:Protection",
        "m2:Process"
      ]
    },

    {
      "@id": "m0:Pole3_Release",
      "@type": ["owl:NamedIndividual", "m0:SynapticPole"],
      "rdfs:label": "Pole 3: Exocytotic Release",
      "m0:poleNumber": 3,
      "m0:location": "Presynaptic active zone (specialized release site)",
      "m0:function": "Calcium-triggered fusion of vesicles with presynaptic membrane, releasing neurotransmitter into synaptic cleft",
      
      "m0:mechanism": {
        "trigger": "Action potential arrives → Voltage-gated Ca²⁺ channels (N-type, P/Q-type) open → Ca²⁺ influx (local [Ca²⁺] rises to ~10-100 μM in nanodomains)",
        "SNAREmachinery": [
          "Synaptobrevin/VAMP2 (vesicle membrane)",
          "Syntaxin-1 (presynaptic membrane)",
          "SNAP-25 (presynaptic membrane)",
          "SNARE complex formation → membrane fusion"
        ],
        "calciumSensor": "Synaptotagmin (C2 domains bind Ca²⁺ and phospholipids, triggers fusion)",
        "cooperativity": "Fusion probability ∝ [Ca²⁺]⁴ (4th order Hill coefficient)",
        "kinetics": "Fast (synchronous release, <1 ms) vs. slow (asynchronous release, tens of ms)"
      },

      "m0:output": "Neurotransmitter molecules released into synaptic cleft (quantal release: ~7000 molecules/vesicle at NMJ, fewer at central synapses)",
      
      "m0:regulation": {
        "releaseProbability": "P_release varies 0.1-0.9 depending on synapse type, activity history",
        "facilitation": "Residual Ca²⁺ from prior spikes increases P_release (short-term plasticity)",
        "autoreceptors": "Negative feedback (e.g., α2-adrenergic on NE terminals, 5-HT1B/D on serotonin terminals)",
        "activeZoneProteins": "RIM, Munc13, liprin-α organize release sites"
      },

      "m0:pharmacologicalTargets": {
        "BotulinumToxin": "Cleaves SNARE proteins (synaptobrevin, SNAP-25, syntaxin depending on serotype), blocks release. Clinical uses: cosmetic (wrinkles), dystonia, migraine, hyperhidrosis.",
        "TetanusToxin": "Cleaves synaptobrevin in inhibitory synapses → spastic paralysis",
        "CalciumChannelBlockers": "ω-Conotoxin (N-type blocker), ω-Agatoxin (P/Q-type blocker) - research tools; Ziconotide (synthetic ω-conotoxin) for severe chronic pain",
        "Baclofen": "GABA_B agonist, reduces Ca²⁺ influx via G-protein inhibition of Ca²⁺ channels (muscle relaxant)"
      },

      "m0:pathology": {
        "Botulism": "Botulinum toxin from Clostridium botulinum → flaccid paralysis",
        "Tetanus": "Tetanus toxin from Clostridium tetani → spastic paralysis",
        "LambertEatonSyndrome": "Autoantibodies against presynaptic Ca²⁺ channels → reduced release → muscle weakness",
        "Congenitalmyasthenicsyndrome": "Mutations in synaptic proteins (e.g., synaptotagmin) → impaired release"
      },

      "m0:metaconceptsInvolved": [
        "m2:Event",
        "m2:Threshold",
        "m2:Signal",
        "m2:Flow",
        "m2:Coupling",
        "m2:Determination",
        "m2:Synergy"
      ]
    },

    {
      "@id": "m0:Pole4_Reception",
      "@type": ["owl:NamedIndividual", "m0:SynapticPole"],
      "rdfs:label": "Pole 4: Postsynaptic Reception",
      "m0:poleNumber": 4,
      "m0:location": "Postsynaptic membrane (dendritic spines, soma)",
      "m0:function": "Neurotransmitter binding to specific receptors, transducing chemical signal into electrical signal (EPSP or IPSP)",
      
      "m0:mechanism": {
        "receptorTypes": {
          "ionotropic": "Ligand-gated ion channels. Fast (ms). Direct coupling. Examples: AMPA/NMDA (glutamate, excitatory), GABA_A (inhibitory), nicotinic (ACh, excitatory), glycine (inhibitory).",
          "metabotropic": "G-protein coupled receptors (GPCRs). Slow (tens of ms to seconds). Indirect via second messengers. Examples: mGluR, GABA_B, muscarinic ACh, adrenergic, dopaminergic, serotonergic."
        },
        "binding": "Neurotransmitter-receptor interaction (lock-and-key, K_d ~nM-μM)",
        "transduction": "Ionotropic: NT binding → channel opening → ion flux (Na⁺, K⁺, Ca²⁺, Cl⁻) → membrane potential change. Metabotropic: NT binding → G-protein activation → second messengers (cAMP, IP3, DAG) → ion channels or gene transcription."
      },

      "m0:output": "Postsynaptic potential: EPSP (depolarization, excitatory) or IPSP (hyperpolarization, inhibitory)",
      
      "m0:receptorExamples": {
        "glutamate": "AMPA (fast EPSP), NMDA (Ca²⁺ entry, plasticity), mGluR (modulatory)",
        "GABA": "GABA_A (fast IPSP, Cl⁻ influx), GABA_B (slow IPSP, K⁺ efflux)",
        "acetylcholine": "Nicotinic (fast EPSP, Na⁺/K⁺), muscarinic (slow, modulatory)",
        "dopamine": "D1-like (D1, D5 - increase cAMP), D2-like (D2, D3, D4 - decrease cAMP)",
        "serotonin": "15+ subtypes (5-HT1-7), mostly metabotropic except 5-HT3 (ionotropic)",
        "norepinephrine": "α1, α2, β1, β2, β3 (all metabotropic)"
      },

      "m0:regulation": {
        "desensitization": "Receptor inactivation during prolonged exposure (e.g., AMPA receptor endocytosis)",
        "trafficking": "Activity-dependent insertion/removal of receptors (LTP/LTD mechanism)",
        "subunitComposition": "Developmentally regulated (e.g., NR2B→NR2A switch in NMDA receptors)",
        "allostericModulation": "Benzodiazepines potentiate GABA_A, Mg²⁺ blocks NMDA"
      },

      "m0:pharmacologicalTargets": {
        "Antipsychotics": "Dopamine D2 antagonists (schizophrenia). Examples: Haloperidol, Risperidone, Olanzapine.",
        "Benzodiazepines": "GABA_A positive allosteric modulators (anxiety, sedation). Examples: Diazepam, Lorazepam, Alprazolam.",
        "LSD": "5-HT2A agonist (hallucinogen)",
        "Naloxone": "μ-opioid receptor antagonist (opioid overdose reversal)",
        "Atropine": "Muscarinic antagonist (anticholinergic, used in bradycardia, organophosphate poisoning)",
        "Curare": "Nicotinic antagonist (neuromuscular blocker, paralytic)",
        "Ketamine": "NMDA receptor antagonist (anesthetic, rapid antidepressant)",
        "AMPAkines": "AMPA receptor positive modulators (cognitive enhancement, experimental)"
      },

      "m0:pathology": {
        "MyastheniaGravis": "Autoantibodies against nicotinic ACh receptors at NMJ → muscle weakness",
        "Schizophrenia": "Hypothesized dopamine dysregulation (D2 overactivity in mesolimbic, D1 underactivity in PFC)",
        "Epilepsy": "GABA_A receptor mutations or glutamate overactivity → hyperexcitability",
        "Depression": "Monoamine receptor sensitivity changes (5-HT, NE receptor downregulation hypothesis)"
      },

      "m0:metaconceptsInvolved": [
        "m2:Signal",
        "m2:Transformation",
        "m2:Specificity",
        "m2:Code",
        "m2:Threshold",
        "m2:Coupling",
        "m2:Adaptation"
      ]
    },

    {
      "@id": "m0:Pole5_Termination",
      "@type": ["owl:NamedIndividual", "m0:SynapticPole"],
      "rdfs:label": "Pole 5: Signal Termination",
      "m0:poleNumber": 5,
      "m0:location": "Synaptic cleft + presynaptic membrane + astrocytes",
      "m0:function": "Rapid removal of neurotransmitter from synaptic cleft to ensure temporal precision and prevent receptor saturation",
      
      "m0:mechanism": {
        "presynapticReuptake": {
          "description": "Neurotransmitter transporter proteins recapture NT into presynaptic terminal for recycling",
          "transporters": [
            "SERT (Serotonin Transporter - 5-HTT)",
            "DAT (Dopamine Transporter)",
            "NET (Norepinephrine Transporter)",
            "GAT (GABA Transporter - multiple subtypes)",
            "EAAT (Excitatory Amino Acid Transporter - glutamate, primarily on astrocytes)"
          ],
          "energetics": "Na⁺ gradient-driven (secondary active transport). Na⁺/K⁺-ATPase maintains gradient."
        },
        "enzymaticDegradation": {
          "acetylcholinesterase": "Hydrolyzes acetylcholine → choline + acetate. Extremely fast (k_cat ~10⁴ s⁻¹). Localized in synaptic cleft.",
          "MAO": "Monoamine oxidase (MAO-A, MAO-B) in mitochondria. Degrades monoamines (dopamine, serotonin, norepinephrine) after reuptake.",
          "COMT": "Catechol-O-methyltransferase. Degrades catecholamines (dopamine, norepinephrine, epinephrine)."
        },
        "diffusion": "Neurotransmitter diffuses away from synaptic cleft (spillover, volume transmission). Minor pathway but relevant for modulatory transmitters."
      },

      "m0:output": "Cleared synaptic cleft, ready for next transmission. Recycled NT or degradation products.",
      
      "m0:regulation": {
        "transporterExpression": "Activity-dependent regulation. Chronic drug exposure alters transporter density.",
        "allostericModulation": "Some transporters have allosteric sites (e.g., amphetamine causes DAT reversal)",
        "glialUptake": "Astrocytes express glutamate transporters (EAAT1/2), critical for preventing excitotoxicity"
      },

      "m0:pharmacologicalTargets": {
        "SSRIs": "Selective Serotonin Reuptake Inhibitors. Block SERT. Examples: Fluoxetine (Prozac), Sertraline (Zoloft), Escitalopram (Lexapro). Indications: Depression, anxiety, OCD.",
        "SNRIs": "Serotonin-Norepinephrine Reuptake Inhibitors. Block SERT + NET. Examples: Venlafaxine, Duloxetine. Indications: Depression, neuropathic pain.",
        "Cocaine": "Blocks DAT, NET, SERT (non-selective). Increases synaptic dopamine → euphoria, addiction.",
        "Amphetamine": "Reverses DAT (and NET), causes dopamine release + reuptake blockade. Clinical: ADHD (Adderall), narcolepsy. Abuse: Methamphetamine.",
        "Donepezil": "Acetylcholinesterase inhibitor (reversible). Alzheimer's disease (increases synaptic ACh in cortex/hippocampus).",
        "Rivastigmine": "Acetylcholinesterase + butyrylcholinesterase inhibitor. Alzheimer's and Parkinson's dementia.",
        "MAOinhibitors": "Prevent monoamine degradation. Examples: Selegiline (MAO-B selective, Parkinson's), Phenelzine (non-selective, depression - older class, dietary restrictions due to tyramine interaction).",
        "Entacapone": "COMT inhibitor. Adjunct to L-DOPA in Parkinson's (reduces peripheral dopamine degradation)."
      },

      "m0:pathology": {
        "Depression": "SERT polymorphisms associated with vulnerability. SSRIs effective treatment.",
        "ADHD": "DAT variants implicated. Stimulants (methylphenidate, amphetamine) block/reverse DAT.",
        "Addiction": "DAT blockade (cocaine) or reversal (amphetamine) central to reward circuitry hijacking.",
        "Alzheimers": "Cholinergic neuron degeneration → reduced ACh. AChE inhibitors provide symptomatic relief."
      },

      "m0:metaconceptsInvolved": [
        "m2:Process",
        "m2:Regulation",
        "m2:Feedback",
        "m2:Homeostasis",
        "m2:Flow",
        "m2:Constraint",
        "m2:Channel"
      ]
    },

    {
      "@id": "m0:MetaconceptMobilization",
      "@type": "owl:NamedIndividual",
      "rdfs:label": "Metaconcepts Mobilized in Complex Chemical Synapse",
      "m0:totalMetaconcepts": 22,
      "m0:coveragePercentage": 40.0,
      "m0:catalogSize": 55,

      "m0:primaryMetaconcepts": [
        {
          "@id": "m2:Component",
          "m0:instances": "5 poles (Synthesis, Storage, Release, Reception, Termination)",
          "m0:strength": "Very High",
          "m0:formula": "Individual pole formulas",
          "m0:rationale": "Each pole is a functional component. Removal of any component destroys system (high coupling). 5-component system (unusual compared to typical 3-pole poclets)."
        },
        {
          "@id": "m2:Synergy",
          "m0:strength": "Very High",
          "m0:formula": "A⊗S⊗I",
          "m0:rationale": "Synaptic transmission emerges from interaction of all 5 poles. No pole alone produces signal. Non-linear: timing synchronization critical (all poles must act in concert). Removal of any pole → zero transmission (emergent phenomenon lost)."
        },
        {
          "@id": "m2:Process",
          "m0:strength": "Very High",
          "m0:formula": "F⊗D (with temporal integration)",
          "m0:rationale": "Sequential process: Synthesis → Storage → Release → Reception → Termination. Cyclic: Termination enables next transmission round. Temporal constraints: each step has characteristic timescale (ms to seconds)."
        },
        {
          "@id": "m2:Flow",
          "m0:strength": "Very High",
          "m0:formula": "F (but F⊗D for directed flow)",
          "m0:rationale": "Material flow (NT synthesis→degradation), energy flow (ATP), information flow (AP→Ca²⁺→NT→EPSP/IPSP). Directionality (presynaptic→postsynaptic, asymmetric). Quantifiable flux rates."
        },
        {
          "@id": "m2:Interdependence",
          "m0:strength": "Very High",
          "m0:formula": "I⊗A⊗S",
          "m0:rationale": "High coupling: failure of any pole → total system failure. Interfaces: molecular (NT-receptor), spatial (cleft geometry), temporal (synchronization). Feedback: autoreceptors (Pole 5→Pole 3 negative feedback)."
        },
        {
          "@id": "m2:Regulation",
          "m0:strength": "High",
          "m0:formula": "A⊗S⊗F",
          "m0:rationale": "Autoreceptors (negative feedback on release), vesicle pool dynamics (RRP vs. reserve pool), calcium buffering, receptor desensitization. Multiple regulatory layers ensure homeostasis."
        },
        {
          "@id": "m2:Signal",
          "m0:strength": "Very High",
          "m0:formula": "I⊗D (with encoding S)",
          "m0:rationale": "Action potential encodes information (frequency, timing). NT concentration encodes signal strength. Receptor response decodes signal. Temporal precision (~ms) critical for neural coding."
        },
        {
          "@id": "m2:Code",
          "m0:strength": "High",
          "m0:formula": "I⊗D⊗S",
          "m0:rationale": "Rate code (firing frequency→intensity), temporal code (spike timing→information), population code (many synapses integrate), chemical code (NT type→sign: excitatory vs. inhibitory)."
        },
        {
          "@id": "m2:Threshold",
          "m0:strength": "High",
          "m0:formula": "I⊗D (with critical transition)",
          "m0:rationale": "Action potential threshold (all-or-none), Ca²⁺ threshold for vesicle fusion (cooperative, 4th-order Ca²⁺ dependence), receptor activation threshold, spike initiation zone threshold."
        },
        {
          "@id": "m2:Channel",
          "m0:strength": "High",
          "m0:formula": "I⊗F (with directionality A)",
          "m0:rationale": "Physical channel (synaptic cleft ~20-40 nm), chemical channel (NT-receptor specificity), temporal channel (transmission window ~0.5-5 ms), information channel (bandwidth limited by refractory period)."
        },
        {
          "@id": "m2:Memory",
          "m0:strength": "High",
          "m0:formula": "∫(D⊗F)dt (temporal integration)",
          "m0:rationale": "Short-term: synaptic plasticity (facilitation, depression). Long-term: LTP/LTD (structural changes, receptor trafficking). Molecular: Ca²⁺-dependent kinases (CaMKII). Structural: spine growth/shrinkage."
        },
        {
          "@id": "m2:Adaptation",
          "m0:strength": "High",
          "m0:formula": "D⊗S (with feedback F)",
          "m0:rationale": "Homeostatic plasticity (maintains network stability), receptor trafficking (up/down regulation), vesicle pool dynamics (activity-dependent replenishment), autoreceptor sensitivity adjustment."
        }
      ],

      "m0:secondaryMetaconcepts": [
        "m2:Constraint",
        "m2:Space",
        "m2:Event",
        "m2:Emergence",
        "m2:Feedback",
        "m2:Specificity",
        "m2:Transformation",
        "m2:Coupling",
        "m2:Homeostasis",
        "m2:Balance",
        "m2:Trade-off"
      ],

      "m0:metaconceptDistribution": {
        "Structural": ["Component", "Space", "Channel"],
        "Dynamical": ["Process", "Flow", "Event"],
        "Relational": ["Synergy", "Interdependence", "Coupling"],
        "Regulatory": ["Regulation", "Threshold", "Homeostasis", "Balance", "Trade-off"],
        "Informational": ["Signal", "Code", "Specificity"],
        "Temporal": ["Memory", "Adaptation"],
        "Systemic": ["Constraint", "Feedback", "Emergence", "Transformation"]
      }
    },

    {
      "@id": "m0:ComparativeAnalysis",
      "@type": "owl:NamedIndividual",
      "rdfs:label": "Comparative Analysis with Other Poclets",
      
      "m0:vsFireTriangle": {
        "similarities": [
          "Both Territory-dominant (physical phenomena with pedagogical Map)",
          "Both exhibit strong Synergy (emergent property from pole interaction)",
          "Both have 'removal effect' (remove any pole → system fails)",
          "Both validated over ~100 years",
          "Both highly actionable (Fire: extinguishment strategies; Synapse: drug targeting)"
        ],
        "differences": {
          "complexity": "Synapse has 5 poles vs. Fire's 3 (reflects biological sophistication)",
          "epistemicGap": "Synapse ΔΘ=0.25 (smaller) vs. Fire ΔΘ=0.47 (model more accurate for synapse)",
          "ORIVEquality": "Synapse 0.87 vs. Fire 0.85 (comparable, both Excellent)",
          "application": "Fire = safety training (pedagogical); Synapse = pharmacology + research + medicine (scientific/clinical)",
          "modularity": "Synapse poles more independently modulable (each pole = drug target)"
        }
      },

      "m0:vsExposureTriangle": {
        "similarities": [
          "Both validated over ~100 years",
          "Both exhibit Balance (Exposure: ISO⊗Aperture⊗Shutter equilibrium; Synapse: E-I balance, homeostasis)",
          "Both exhibit Trade-off (Exposure: DoF vs. grain vs. motion; Synapse: speed vs. reliability vs. energy)",
          "Both have excellent Map quality (Exposure ORIVE=0.92; Synapse ORIVE=0.87)"
        ],
        "differences": {
          "poles": "Exposure has 3 poles; Synapse has 5 poles",
          "dominance": "Exposure is Map-dominant (human operator makes trade-offs); Synapse is Territory-dominant (evolution optimized trade-offs)",
          "epistemicGap": "Exposure ΔΘ=0.32 vs. Synapse ΔΘ=0.25 (Synapse model slightly more accurate)",
          "agency": "Exposure: photographer decides; Synapse: biological mechanism (no conscious decision-maker)"
        }
      },

      "m0:vsRGB": {
        "similarities": [
          "Both involve transformation (Synapse: chemical→electrical; RGB: spectral→tristimulus)",
          "Both have multiple representations (Synapse: NT types; RGB: color spaces)",
          "Both scientifically validated"
        ],
        "differences": {
          "perspective": "RGB is Map-dominant (human-constructed color model); Synapse is Territory-dominant (biological reality)",
          "poles": "RGB has 3 poles (R, G, B); Synapse has 5 poles",
          "gap": "RGB ΔΘ=0.35 vs. Synapse ΔΘ=0.25 (Synapse model more accurate)"
        }
      }
    },

    {
      "@id": "m0:ValidationEvidence",
      "@type": "owl:NamedIndividual",
      "rdfs:label": "Empirical Validation Evidence",
      
      "m0:pharmacologicalValidation": {
        "drugCount": "100+ validated drugs across all 5 poles",
        "patientYears": "Billions of patient-years of clinical data",
        "predictability": "Blocking any pole disrupts transmission as model predicts. Dose-response curves quantitatively match predictions.",
        "examples": [
          "Pole 1: L-DOPA (Parkinson's - increases dopamine synthesis)",
          "Pole 2: Tetrabenazine (Huntington's - depletes vesicular monoamines)",
          "Pole 3: Botulinum toxin (SNARE cleavage - blocks release)",
          "Pole 4: Antipsychotics (D2 antagonism - schizophrenia)",
          "Pole 5: SSRIs (reuptake blockade - depression)"
        ]
      },

      "m0:experimentalValidation": {
        "timeline": "100+ years (Loewi 1921 → present)",
        "techniques": [
          "Electrophysiology: Patch-clamp (whole-cell, outside-out, cell-attached), sharp electrode, voltage clamp",
          "Imaging: Electron microscopy (ultrastructure), fluorescence microscopy (Ca²⁺ imaging, vesicle dynamics, synapto-pHluorin), super-resolution (STED, STORM, PALM)",
          "Molecular: Receptor cloning and expression, SNARE protein purification and reconstitution, optogenetics (channelrhodopsin, halorhodopsin)",
          "Biochemistry: Enzyme assays, neurotransmitter quantification (HPLC, mass spectrometry), radioligand binding"
        ],
        "speciesValidation": "Conserved from C. elegans (302 neurons, all mapped) to Drosophila to mice to humans",
        "NobelPrizes": [
          "Katz (1970): Quantal release theory",
          "Carlsson (2000): Dopamine signaling in brain",
          "Südhof, Rothman, Schekman (2013): Vesicle trafficking and fusion"
        ]
      },

      "m0:clinicalValidation": {
        "neurological": [
          "Myasthenia gravis: Antibodies against nicotinic receptors → muscle weakness (validates Pole 4)",
          "Lambert-Eaton syndrome: Antibodies against presynaptic Ca²⁺ channels → reduced release (validates Pole 3)",
          "Botulism: Botulinum toxin → SNARE cleavage → paralysis (validates Pole 3)",
          "Tetanus: Tetanus toxin → inhibitory synapse blockade → spastic paralysis (validates Pole 3)"
        ],
        "psychiatric": [
          "Depression: SSRI efficacy validates serotonin hypothesis and Pole 5 (reuptake) as target",
          "Schizophrenia: D2 antagonist (antipsychotic) efficacy validates dopamine hypothesis and Pole 4 (reception) as target",
          "ADHD: Stimulant (amphetamine, methylphenidate) efficacy validates dopamine/norepinephrine and Poles 5+3 (reuptake + release) as targets"
        ],
        "neurodegenerative": [
          "Parkinson's disease: L-DOPA efficacy validates dopamine synthesis (Pole 1) and nigrostriatal pathway degeneration",
          "Alzheimer's disease: Acetylcholinesterase inhibitor efficacy validates cholinergic hypothesis and Pole 5 (degradation) as target"
        ]
      }
    },

    {
      "@id": "m0:FutureDirections",
      "@type": "owl:NamedIndividual",
      "rdfs:label": "Future Research and Model Extensions",
      
      "m0:towards6PoleModel": {
        "proposal": "Add Pole 6: Glial Modulation",
        "components": {
          "astrocytes": "Glutamate uptake (EAAT transporters prevent excitotoxicity), K⁺ buffering (maintains resting potential), gliotransmitter release (D-serine, ATP, glutamate modulate synaptic transmission)",
          "microglia": "Synaptic pruning (complement C1q/C3 tagging, CR3 receptor-mediated phagocytosis), immune surveillance, cytokine release",
          "oligodendrocytes": "Myelin affects conduction velocity → temporal integration at synapse. Oligodendrocyte-axon metabolic coupling."
        },
        "prediction": "Adding Pole 6 would increase ORIVE (more explanatory power: explains glial contributions to plasticity, disease, development) but also complexity (6-pole system harder to conceptualize). Might reduce ΔΘ (model captures more of reality)."
      },

      "m0:multiScaleModel": {
        "nanoscale": "Liquid-liquid phase separation in active zones (synapsin, RIM, Munc13 form condensates). Single-molecule tracking (NT-receptor binding kinetics). Super-resolution structure (nanodomains, Ca²⁺ channel-vesicle coupling distance <10 nm).",
        "mesoscale": "Synaptic plasticity (LTP/LTD), spine dynamics (actin remodeling, spine growth/shrinkage), receptor trafficking (AMPA receptor insertion/removal, lateral diffusion).",
        "networkScale": "Circuit dynamics (recurrent excitation/inhibition), oscillations (gamma, theta, delta), synchronization (coherence, phase-locking).",
        "TSCGapplication": "Could analyze each scale with separate ASFID/ORIVE metrics. Multi-level ontology: Pole (M0) → Synapse (M0) → Circuit (M1?) → Brain Region (M1?) → Behavior (M1?)."
      },

      "m0:gapReduction": {
        "currentGap": "ΔΘ = 0.25 (75% of complexity captured)",
        "strategies": [
          "Incorporate glial cells (astrocytes, microglia) → reduce gap to ~0.20",
          "Model nanoscale organization (Ca²⁺ nanodomains, phase separation) → reduce gap to ~0.18",
          "Include non-canonical pathways (non-vesicular release, volume transmission) → reduce gap to ~0.15",
          "Multi-scale integration (nano→meso→network) → reduce gap to ~0.10"
        ],
        "tradeoff": "Reducing gap increases model complexity (harder to teach, use). Optimal gap depends on purpose (pedagogy vs. research vs. simulation)."
      }
    }
  ]
}
